Alnylam’s Drug Fails to Lower Blood Pressure in Trial
“`html
Alnylam’s Zilebesiran fails to Meet Primary Endpoint in Phase 2 Hypertension Trial
Key Summary
An investigational therapy, zilebesiran, developed by Alnylam Pharmaceuticals, did not demonstrate statistically critically important blood pressure reduction in a Phase 2 clinical trial among high-risk hypertension patients already on existing medications. The results, presented at the european society of Cardiology meeting on August 30, 2024, raise concerns about the drug’s efficacy as it progresses to Phase 3 testing. While a reduction in blood pressure was observed compared to placebo, the difference was not large enough to be considered statistically significant.
Trial Details and Results
The Phase 2 trial involved patients with hypertension who were already receiving at least two existing blood pressure medications. Researchers evaluated two doses of zilebesiran: 300 mg and 600 mg, against a placebo group. Zilebesiran is designed to reduce blood pressure by silencing the AGT gene, which plays a role in regulating blood pressure.
The 300 mg dose of zilebesiran resulted in a blood pressure reduction of 5 mmHG lower than placebo at three months. However, this difference diminished to 3.9 mmHG by six months. Crucially,neither difference reached statistical importance,meaning the observed reduction could be due to chance. The 600 mg dose did not demonstrate any additional benefit compared to the 300 mg dose.
| timepoint | Zilebesiran 300mg vs. Placebo (mmHG Reduction) | Zilebesiran 600mg vs. Placebo (mmHG Reduction) |
|---|---|---|
| 3 Months | 5.0 | Not Substantially Different |
| 6 Months | 3.9 | Not Significantly Different |
These findings were presented on Saturday, August 30, 2024, at the European Society of Cardiology congress. European Society of Cardiology
Understanding the Implications
Zilebesiran represents a novel approach to hypertension treatment using RNA interference (RNAi) technology. rnai therapies work by silencing specific genes, offering the potential for targeted and long-lasting effects. The initial promise of zilebesiran lay in its potential for twice-yearly administration,which could significantly improve patient adherence compared to daily oral medications.
The lack of statistical significance in the Phase 2 trial doesn’t necessarily halt the development of zilebesiran. However, it does necessitate a careful evaluation of the Phase 3 trial design and endpoints. Alnylam will need to demonstrate a more robust efficacy signal in the larger,late-stage trials to secure regulatory approval.
What is Hypertension and Why Does This Matter?
Hypertension, or high blood pressure, is a major global health concern, affecting approximately 1.13 billion peopel worldwide as of 2024, according to the World Health Organization. It significantly increases the risk of heart disease, stroke, kidney failure, and other serious health